What makes breezula different than formula 82f? Question 1/14/2020
Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.
View this post in the Community →
Similar Community Posts Join
5 / 357 resultscommunity Hey guys I’m a Compounding Pharmacist specialized in Hair-loss who makes Topical Finasteride Foam +/- minoxidil
A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.
community How safe and/or difficult would it theoretically be to turn raw 99.9% clascoterone into topical formula?
The user discusses their hair regrowth success with minoxidil, red light therapy, massage, and derma stamping but expresses concerns about using finasteride due to potential side effects. They are interested in using clascoterone as a topical treatment for hair loss and are exploring the possibility of creating a topical formula from raw clascoterone powder.
community Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
community Will Breezula simply be an overhyped flop?
Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.
community Chat is this real? Compound called clascoterone
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
Related Research
6 / 13 results
research Experimental and early investigational drugs for androgenetic alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research 0951 Breezula, a clinical stage topical anti-androgen, promotes dermal papilla inductivity and reduces IL-6 secretion in balding skin samples ex vivo
Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Antiandrogens and Androgen Inhibitors
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.